Android app on Google Play

Osiris Therapeutics (OSIR) Trades Strong Following Prochymal News; Shares Nearly at Annual Highs

June 14, 2012 2:12 PM EDT Send to a Friend
Osiris Therapeutics, Inc. (Nasdaq: OSIR) shares are moving today on strong volume following an earlier announcement it received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

Volatility on the stock is up 22 points from Wednesday to 96.85 percent.

Shares are up over 11 percent on the session. Earlier, shares were inching closer to a fresh 52-week high at $8.39. Today is actually the highest level shares have been since last July.




You May Also Be Interested In


Related Categories

Insiders' Blog, Options

Add Your Comment